U.S. Capital Markets Stock News

Zeta Global Holdings (ZETA) Q1 2026 earnings snapshot Zeta Global Holdings (ZETA) opened 2026 with Q1 revenue of US$396.3 million and a basic EPS loss of US$0.05 per share, while the trailing 12 month figures show US$1.4 billion of revenue and a net loss of US$23.2 million. Over the past five reported quarters, revenue has moved from US$264.4 million in Q1 2025 to US$396.3 million in Q1 2026, while basic EPS has ranged between a loss of US$0.10 and a profit of US$0.07 per share across that...

Wondering whether McEwen's current share price reflects its real worth, or if the stock is getting ahead of itself. The share price last closed at US$21.30, with returns of 14.0% year to date and 189.4% over the past year, while the last 7 days saw a 12.2% decline and the last 30 days were flat at a 0.5% decline. Recent coverage has focused on McEwen's strong one year return of 189.4%. This stands out against its more moderate 3 year and 5 year returns of 138.8% and 63.8%. This context...

Piedmont Realty Trust (PDM) opened 2026 with Q1 revenue of US$143.3 million and basic EPS of a US$0.10 loss, while trailing 12 month revenue was US$565.6 million and EPS was a US$0.69 loss. Over the past year, the company’s quarterly revenue moved from US$142.7 million in Q1 2025 to US$143.3 million in Q1 2026, with basic EPS shifting from a Q1 2025 loss of US$0.08 per share to a Q1 2026 loss of US$0.10 per share as investors consider how these margins may influence any potential...

Mohawk Industries (MHK) opened 2026 with Q1 revenue of US$2.7 billion and basic EPS of US$1.91, setting the tone for how investors weigh the latest numbers against trailing profitability and growth expectations. Over the past few quarters, revenue has moved between US$2.5 billion in Q1 2025 and US$2.8 billion in Q2 2025, while basic EPS ranged from US$0.68 in Q4 2025 to US$2.35 in Q2 2025, providing a view of how earnings have tracked relative to a fairly steady top line. With trailing net...

nLIGHT (NasdaqGS:LASR) is expanding its operations in Torino, Italy to support rising regional demand for directed energy and high power laser solutions. The move is intended to serve European and allied customers with regionally tailored products and improve localization and supply chain resilience. This expansion marks a material step in nLIGHT's international build out and its focus on defense related laser technologies. For investors tracking nLIGHT, the expansion comes with the shares...

Next Technology Holding (NasdaqCM:NXTT) opened 2026 with Q1 revenue of about US$0.5 million and a basic EPS loss of US$1.39 per share, alongside a net loss of US$105.9 million. Over recent quarters the company has seen revenue move from US$0 in Q1 2025 to US$9.8 million in Q4 2025 before landing at US$0.5 million in Q1 2026. EPS has swung from a very high profit of US$396.38 per share in Q1 2025 to a loss of US$1.39 in the latest quarter, setting a backdrop where reported margins look highly...

Brookfield Infrastructure (NYSE:BIPC) has opened 2026 with Q1 revenue of US$884 million and a basic EPS loss of US$0.93, setting the tone for another quarter where the income statement matters more than headline growth stories. Over the past year, quarterly revenue has ranged from US$866 million to US$956 million while EPS has swung between a gain of US$3.27 and a loss of US$4.01, highlighting how volatile profitability has been for shareholders watching margins. See our full analysis for...

Wondering whether Blackbaud at around US$37.54 is a bargain or a value trap? This breakdown will help you size up what the current share price really reflects. The stock has been broadly flat over the last month at around 0.0%. However, that sits against a much tougher backdrop with a 36.9% decline year to date and a 38.9% decline over the past year. Those longer term returns mean many holders are sitting on losses, which often pushes valuation questions to the front of investors' minds...

Pro-Dex (PDEX) has put up a solid Q3 2026 print, with revenue of about US$19.9 million and basic EPS of roughly US$1.23, against a trailing twelve month backdrop where earnings grew 28.1% year over year and net profit margin sat at 16.1%. Over recent quarters the company has seen revenue move from around US$17.4 million in Q3 2025 to US$19.9 million in Q3 2026, while quarterly basic EPS ranged between roughly US$0.37 and US$1.43 over that stretch, giving a clear view of how revenue and per...

American International Group (AIG) opened 2026 with Q1 results that put the focus squarely on the income statement, as revenue came in at US$6.7b and basic EPS landed at US$1.42 on net income of US$763m. The company has seen revenue move from US$6.5b in Q1 2025 to US$6.7b in Q1 2026, while basic EPS over that stretch ranged from US$1.18 in Q1 2025 to US$1.42 in the latest quarter. This sets the stage for investors to weigh these headline figures against a backdrop of improving trailing net...

OneSpan (OSPN) Q1 2026 earnings snapshot OneSpan (OSPN) has opened 2026 with Q1 revenue of US$65.9 million and basic EPS of US$0.31, setting the tone for investors assessing how the business is converting its software demand into bottom line results. Over the past year, the company has seen trailing twelve month revenue sit at US$245.8 million with basic EPS of US$1.84, alongside earnings growth of 20.4% and net margins at 28.5% compared to 24% a year earlier. This provides useful context for...

LPL Financial Holdings (LPLA) opened 2026 with Q1 revenue of about US$4.8b and basic EPS of US$4.45, as investors weigh these headline figures against a reported net margin of 5% over the trailing 12 months that was affected by a US$732.0m one off loss. The company has seen quarterly revenue move from US$3.4b in Q4 2024 to US$3.6b in Q1 2025 and then to about US$4.8b in Q1 2026. Over the last six reported periods, trailing 12 month basic EPS has ranged from US$14.17 to US$11.25, placing...

Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer. The company elevated Andrew King, M.D., Ph.D. to President, Research & Development. These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline. Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...

PBF Energy (PBF) opened 2026 with Q1 revenue of US$7.9b and basic EPS of US$1.69, alongside net income excluding extra items of US$198.3m, setting a clear marker after a volatile run of recent quarters. The company has seen quarterly revenue move from US$7.1b in Q1 2025 to US$7.9b in Q1 2026, while EPS shifted from a loss of US$3.53 in Q1 2025 to a profit of US$1.69 in the latest period. This points to a very different margin profile as investors gauge how durable this reset may be. See our...

Investors may be wondering whether Aurora Innovation's share price reflects its true worth, or if the market is mispricing the story right now. The stock recently closed at US$6.13, with returns of 24.8% over 7 days, 46.7% over 30 days, 58.4% year to date, and a 24.7% decline over the past year, alongside a very large gain over 3 years. Recent coverage has focused on how autonomous driving and AI related names are being reassessed by investors, as attention shifts to companies tied to real...

If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can help frame your next move. The stock has seen sharp swings recently, with returns of 11.6% over 7 days, 22.5% over 30 days, 34.6% year to date, but a 29.3% decline over the past year and gains of 113.6% over 3 years and 143.7% over 5 years. Recent coverage has focused on how this price history shapes expectations for Corcept...

For investors considering whether Travelers Companies at around US$304.72 represents fair value or whether the price may be ahead of itself, this article examines what the available numbers indicate about the stock. The share price has moved by 0.7% over the past week, 4.9% over the last month, 6.8% year to date and 15.8% over the past year. These figures provide useful context before assessing the underlying value. Recent news coverage has focused on Travelers Companies as a major U.S...

Omega Healthcare Investors (OHI) opened 2026 with Q1 revenue of US$323 million and basic EPS of US$0.47, alongside funds from operations of US$249 million and FFO per share of US$0.84, setting a clear snapshot of cash generation and earnings at the start of the year. Over the past reported quarters, revenue has moved from US$277 million in Q1 2025 to US$319 million in Q4 2025 and EPS has ranged between US$0.34 and US$0.60 over that period. This gives investors a recent history of how the top...

Wondering if American Healthcare REIT is reasonably priced at around US$50 a share, or if the market is getting ahead of itself? This article walks through what the current numbers actually say about value. The stock recently closed at US$50.15, with returns of 0.1% over 7 days, 5.5% over 30 days, 6.2% year to date and 57.7% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on American Healthcare...

Align Technology (ALGN) opened 2026 with Q1 revenue of about US$1.0 billion and basic EPS of US$1.58, setting the tone for how investors will read the rest of the year. The company has seen quarterly revenue move from US$979.3 million in Q1 2025 through US$995.2 million in Q4 2024 to just over US$1.0 billion in the latest quarter, while basic EPS over the same span ranged from US$1.27 in Q1 2025 to US$1.89 in Q4 2025 before landing at US$1.58 in Q1 2026. This provides a clear run-rate on both...

O'Reilly Automotive (ORLY) opened 2026 with Q1 revenue of US$4.6b and basic EPS of US$0.72, supported by trailing twelve month revenue of US$18.2b and EPS of US$3.08 that point to earnings growth of 9.5% over the past year. Over the last five reported quarters, the company has seen revenue move from US$4.1b in Q1 2025 to US$4.6b in Q1 2026, while quarterly EPS ranged between US$0.63 and US$0.86 across that period as trailing net income reached US$2.6b. With net profit margins running at...

This article examines whether StoneCo, trading at around US$10.98, could be considered a bargain or a value trap by focusing on what the current share price might imply about the company. The stock has experienced significant recent volatility, with a 24.5% decline over the last week, a 22.2% decline over the last month, and a 25.3% decline year to date. Over longer periods, the 1 year return shows a 4.3% decline and the 5 year return a 78.3% decline. Recent commentary around StoneCo has...

Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions. The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron. Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects. The presentations focus on combination approaches in obesity and diabetes treatment development. Structure Therapeutics focuses on oral...

If you are wondering whether Camtek's current share price reflects its underlying value, you are not alone. That question is exactly what this article will help you think through. Camtek's stock has been volatile recently, with a 2% decline over the last week, a 26.6% gain over the last 30 days, a 66.2% return year to date, and a 191.3% return over the last year, along with very large multi year gains. These moves have put Camtek firmly on many investors' radars, and recent coverage has...